2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2893

Usefulness of the Eustar Preliminary Criteria for Vey Early Systemic Sclerosis and Le Roy Criteria for Early-Systemic Sclerosis in Identifying Patients at Risk of Development of Systemic Sclerosis
Abstract Number: 967

Using a Hazard Index Tool Based on Short Term Renal Parameters to Predict Long Term Outcomes in Lupus Nephritis: A Novel Way to Assess New Therapies
Abstract Number: 305

Using a Large Prospective Cohort of Patients to Examine Differences in Performance and Self-Reported Outcomes Following Total Knee Replacement
Abstract Number: 1157

Using Goutpro to Make Medical Trainees Gout Pros
Abstract Number: 2635

Using Patient Reported Outcomes to Inform a Treat to Target Treatment Approach in RA
Abstract Number: 1423

Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis
Abstract Number: 1426

Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis
Abstract Number: 787

Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Measure Disease Severity in Discoid Lupus Erythematosus
Abstract Number: 1707

Ustekinumab and the Comparative Risk for Acute Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 1718

Ustekinumab, Apremilast, TNFi and the Risk for Hospitalized Infection in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 862

Utility of 18f FDG Positron Emission Tomography (PET) As a Diagnostic Test and Marker of Disease Activity in Large Vessel Vasculitis
Abstract Number: 1293

Utility of Extremity Magnetic Resonance Imaging (eMRI) without Contrast Enhancement in Detecting Preclinical Psoriatic Arthritis
Abstract Number: 1283

Utility of FDG-PET Imaging and Serological Biomarkers for Diagnosing Lymphadenopathy of IgG4-Related Diseas
Abstract Number: 3180

Utility of Measurements of Urinary Soluble CD163 & MCP-1 in the Identification of Subtle Renal Flares in ANCA-Associated Vasculitis
Abstract Number: 999

Utility of Neutrophil CD64 Expression & sTREM-1 in Distinguishing Bacterial Infection from Disease Flare in SLE and ANCA Associated Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].